# Melvin L K Chua

## List of Publications by Citations

Source: https://exaly.com/author-pdf/3184371/melvin-l-k-chua-publications-by-citations.pdf

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 137
 4,716
 26
 67

 papers
 citations
 h-index
 g-index

 174
 6,436
 7.2
 6.18

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
137	Nasopharyngeal carcinoma. <i>Lancet, The</i> , <b>2016</b> , 387, 1012-1024	40	799
136	SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1108-1110	13.4	656
135	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , <b>2020</b> , 25, e936-e945	5.7	356
134	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , <b>2017</b> , 541, 359-364	50.4	320
133	Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1124-1135	59.2	297
132	Molecular landmarks of tumor hypoxia across cancer types. <i>Nature Genetics</i> , <b>2019</b> , 51, 308-318	36.3	255
131	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , <b>2019</b> , 176, 831-843.6	<b>23</b> 6.2	214
130	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. <i>Cell</i> , <b>2018</b> , 173, 1003-1013.e15	56.2	115
129	Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma. <i>Radiology</i> , <b>2019</b> , 291, 677-686	20.5	113
128	Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. <i>Annals of Oncology</i> , <b>2019</b> , 30, 68-75	10.3	108
127	A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , <b>2017</b> , 72, 665-674	10.2	98
126	Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. <i>Head and Neck</i> , <b>2009</b> , 31, 346-54	4.2	72
125	Mitochondrial mutations drive prostate cancer aggression. <i>Nature Communications</i> , <b>2017</b> , 8, 656	17.4	66
124	Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1345-1352	13.4	64
123	Upconversion superballs for programmable photoactivation of therapeutics. <i>Nature Communications</i> , <b>2019</b> , 10, 4586	17.4	58
122	Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. <i>Cancer</i> , <b>2020</b> , 126, 4023-4031	6.4	57
121	Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. <i>Nature Communications</i> , <b>2019</b> , 10, 3941	17.4	55

120	Neuropathological and transcriptomic characteristics of the aged brain. ELife, 2017, 6,	8.9	50	
119	Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 99, 362-6	5.3	47	
118	Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 891-899	2.2	45	
117	SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan		42	
116	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 840-859	2.2	42	
115	Pan-cancer analysis connects tumor matrisome to immune response. <i>Npj Precision Oncology</i> , <b>2019</b> , 3, 15	9.8	36	
114	Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials. <i>European Journal of Cancer</i> , <b>2016</b> , 67, 119-129	7.5	34	
113	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , <b>2017</b> , 72, 22-31	10.2	28	
112	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1073-1079	13.4	26	
111	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , <b>2019</b> , 25, 1615-1626	50.5	25	
110	DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy. <i>Radiation and Environmental Biophysics</i> , <b>2014</b> , 53, 355-64	2	25	
109	Comparison of radiomics tools for image analyses and clinical prediction in nasopharyngeal carcinoma. <i>British Journal of Radiology</i> , <b>2019</b> , 92, 20190271	3.4	23	
108	Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19. JAMA Oncology, <b>2021</b> , 7, 597-602	13.4	23	
107	Dysregulation of the MiR-449b target TGFBI alters the TGFIpathway to induce cisplatin resistance in nasopharyngeal carcinoma. <i>Oncogenesis</i> , <b>2018</b> , 7, 40	6.6	23	
106	Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. <i>Annals of Oncology</i> , <b>2019</b> , 30, 637-643	10.3	21	
105	Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma. <i>Chinese Clinical Oncology</i> , <b>2018</b> , 7, 15	2.3	21	
104	Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review. <i>JAMA Oncology</i> , <b>2020</b> , 6, 567-577	13.4	20	
103	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 103, 84-91	4	20	

102	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2305-2314	7.5	19
101	Carcinogenesis of nasopharyngeal carcinoma: an alternate hypothetical mechanism. <i>Chinese Journal of Cancer</i> , <b>2016</b> , 35, 9		19
100	Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors. <i>Cancer Communications</i> , <b>2020</b> , 40, 374-379	9.4	19
99	Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skin. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 99, 225-30	5.3	17
98	Gemcitabine: a game changer in nasopharyngeal carcinoma. <i>Lancet, The</i> , <b>2016</b> , 388, 1853-1854	40	15
97	A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5438-5447	12.9	14
96	Outcomes in Radiotherapy-Treated Patients With Cancer During the COVID-19 Outbreak in Wuhan, China. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1457-1459	13.4	13
95	Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3124-6	12.9	13
94	A Deep Learning-Based Automated CT Segmentation of Prostate Cancer Anatomy for Radiation Therapy Planning-A Retrospective Multicenter Study. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	12
93	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , <b>2021</b> , 4, 570-579	6.7	12
92	De-Escalation Strategies in HPV-Associated Oropharynx Cancer-Are we Putting the Cart Before the Horse?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 705-709	4	11
91	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 682-695	4	11
90	Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 123, 459-465	5.3	10
89	Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. <i>Photodiagnosis and Photodynamic Therapy</i> , <b>2019</b> , 27, 367-374	3.5	10
88	Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). <i>Radiation Oncology</i> , <b>2009</b> , 4, 23	4.2	10
87	Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 1115-22	4.4	10
86	Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. <i>Current Problems in Cancer</i> , <b>2017</b> , 41, 265-272	2.3	9
85	Matrix metalloproteinase-1 facilitates MSC migration via cleavage of IGF-2/IGFBP2 complex. <i>FEBS Open Bio</i> , <b>2018</b> , 8, 15-26	2.7	9

## (2020-2016)

84	Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 119, 244-9	5.3	9
83	A Multicenter Study of Coronavirus Disease 2019 Outcomes of Cancer Patients in Wuhan, China		9
82	Multidisciplinary team meetings - challenges of implementation science. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 205-206	19.4	9
81	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. <i>Nature Communications</i> , <b>2021</b> , 12, 117	17.4	9
80	The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma. <i>Cancer Biology and Medicine</i> , <b>2018</b> , 15, 1-5	5.2	9
79	Stereotactic body radiotherapy for early stage lung cancer-historical developments and future strategies. <i>Chinese Clinical Oncology</i> , <b>2017</b> , 6, S20	2.3	8
78	Intensity-modulated radiotherapy for paranasal sinuses and base of skull tumors. <i>Oral Oncology</i> , <b>2018</b> , 86, 61-68	4.4	8
77	Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. <i>Cancer Biology and Medicine</i> , <b>2019</b> , 16, 157-166	5.2	7
76	Adaptive radiotherapy for head and neck cancers: Fact or fallacy to improve therapeutic ratio?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , <b>2018</b> , 22, 287-295	1.3	6
75	Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy. <i>Cancer Letters</i> , <b>2016</b> , 374, 324-30	9.9	6
74	Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2020</b> , 16, 75-79	1.9	6
73	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. <i>European Urology Oncology</i> , <b>2020</b> ,	6.7	6
72	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , <b>2020</b> , 25, e1426-e1427	5.7	5
71	A nomogram to predict symptomatic epilepsy in patients with radiation-induced brain necrosis. <i>Neurology</i> , <b>2020</b> , 95, e1392-e1403	6.5	5
70	A Prospective 10-Year Observational Study of Reduction of Radiation Therapy Clinical Target Volume and Dose in Early-Stage Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 107, 672-682	4	5
69	Improving the therapeutic ratio of radiotherapy against radioresistant cancers: Leveraging on novel artificial intelligence-based approaches for drug combination discovery. <i>Cancer Letters</i> , <b>2021</b> , 511, 56-6	7 <sup>9.9</sup>	5
68	Recent advances in radiation therapy and photodynamic therapy. <i>Applied Physics Reviews</i> , <b>2021</b> , 8, 0413	3 <b>2</b> 127.3	5
67	Follow-Up and Management of Patients With Head and Neck Cancer During the 2019 Novel Coronavirus (SARS-CoV-2) Disease Pandemic. <i>Advances in Radiation Oncology</i> , <b>2020</b> , 5, 631-636	3.3	4

66	Surgery as an alternative to radiotherapy in early-stage nasopharyngeal carcinoma: innovation at the expense of uncertainty. <i>Cancer Communications</i> , <b>2020</b> , 40, 119-121	9.4	4
65	Germline Polymorphisms and Length of Survival of Nasopharyngeal Carcinoma: An Exome-Wide Association Study in Multiple Cohorts. <i>Advanced Science</i> , <b>2020</b> , 7, 1903727	13.6	4
64	Electronic tumor board presentations as the basis for the development of a head and neck cancer database. <i>Laryngoscope Investigative Otolaryngology</i> , <b>2020</b> , 5, 46-54	2.8	4
63	Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920970050	5.4	4
62	Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 6005-6005	2.2	4
61	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. <i>ESMO Open</i> , <b>2016</b> , 1, e000123	6	3
60	Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol. <i>BMC Cancer</i> , <b>2020</b> , 20, 1045	4.8	3
59	Duration-dependent margins for prostate radiotherapy-apractical motion mitigation strategy. <i>Strahlentherapie Und Onkologie</i> , <b>2020</b> , 196, 657-663	4.3	3
58	Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma. <i>Cancer Communications</i> , <b>2019</b> , 39, 64	9.4	3
57	Exploiting molecular genomics in precision radiation oncology: a marriage of biological and physical precision. <i>Chinese Clinical Oncology</i> , <b>2017</b> , 6, S19	2.3	3
56	Risk of COVID-19 in Patients With Cancer-Reply. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1472-1473	13.4	2
55	Four Influential Clinical Trials in Human Papilloma Virus-Associated Oropharynx Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 106, 893-899	4	2
54	Adolescents and young adults with cancer: Considerations from the Southeast Asian perspective <i>Pediatric Blood and Cancer</i> , <b>2022</b> , e29593	3	2
53	Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis <i>BMJ Open</i> , <b>2022</b> , 12, e044661	3	2
52	Infection Control of 2019 Novel Corona Virus Disease (COVID-19) in Cancer Patients undergoing Radiotherapy in Wuhan		2
51	The metabolic footprint during adipocyte commitment highlights ceramide modulation as an adequate approach for obesity treatment. <i>EBioMedicine</i> , <b>2020</b> , 51, 102605	8.8	2
50	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 108, 70-80	4	2
49	Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study.  Oral Oncology, <b>2021</b> , 115, 105222	4.4	2

## (2021-2021)

48	Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 160, 140-147	5.3	2
47	Reply to Colorectal cancer and COVID-19: Do we need to raise awareness and vigilance?. <i>Cancer</i> , <b>2021</b> , 127, 980-981	6.4	2
46	Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC. <i>BMC Cancer</i> , <b>2018</b> , 18, 1095	4.8	2
45	Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity. <i>Mikrochimica Acta</i> , <b>2021</b> , 189, 14	5.8	2
44	Efficacy, toxicity, and quality-of-life outcomes of ultrahypofractionated radiotherapy in patients with localized prostate cancer: A single-arm phase 2 trial from Asia <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2021</b> ,	1.9	2
43	Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 100, 702-709	4	1
42	Lymphocyte apoptosis as a predictive biomarker for radiotherapy de-intensification in EBV-associated nasopharynx cancer <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e17545-e17545	2.2	1
41	The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 46-46	2.2	1
40	Immune dysregulation underpins radioresistance in nasopharyngeal carcinoma (NPC). <b>2019</b> , 5, 52-52		1
39	An evaluation of concordance between head and neck advanced practice radiation therapist and radiation oncologists in toxicity assessment for nasopharyngeal carcinoma patients. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , <b>2021</b> , 19, 52-56	1.9	1
38	Bevacizumab Combined with Corticosteroids Does Not Improve the Clinical Outcome of Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 746941	5.3	1
37	Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma-Magic Bullet or Pandora's Box?. <i>JAMA Oncology</i> , <b>2022</b> ,	13.4	1
36	JUPITER-02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps <i>Cancer Communications</i> , <b>2021</b> ,	9.4	1
35	Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 1758	88 <del>3:1</del> 92	119052411
34	Why we should give spatially fractionated radiation therapy (GRID) a second look@specially in nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , <b>2018</b> , 1, 1-1	0.3	О
33	A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men. <i>Acta Oncolgica</i> , <b>2021</b> , 60, 1291-1295	3.2	О
32	Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	0
31	Repurposing Proton Beam Therapy through Novel Insights into Tumour Radioresistance. <i>Clinical Oncology</i> , <b>2021</b> , 33, e469-e481	2.8	O

30	In Reply. <i>Oncologist</i> , <b>2020</b> , 25, e1252-e1253	5.7
29	Preliminary outcomes of a prospective observational study of combinatorial abiraterone acetate/enzalutamide (AA/Enz) and radical radiotherapy (RT) in nonmetastatic node-positive (N+M0) prostate cancer (PCa) <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 227-227	2.2
28	The Uro-Oncology Multi-disciplinary team (MDT) Clinic Iclinical and Patient-Reported Outcomes From Implementing a New Model of Care. <i>Proceedings of Singapore Healthcare</i> ,201010582110552	0.5
27	In Reply to Abbasi et al International Journal of Radiation Oncology Biology Physics, 2022, 112, 262-263	4
26	A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 68-68	2.2
25	68-Ga prostate-specific membrane antigen-PET as a diagnostic and clinical decision making tool in biochemical recurrences post-radical prostatectomy <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 377-377	2.2
24	"Cor Occidere": a novel strategy of targeting the tumor core by radiosurgery in a radio- and chemo-resistant intracranial hemangiopericytoma. <i>Chinese Clinical Oncology</i> , <b>2018</b> , 7, 10	2.3
23	Retroperitoneal Knee Pain: An Unusual Case Report and Review of an Ancient Schwannoma. <i>Cureus</i> , <b>2018</b> , 10, e2216	1.2
22	A radiomics signature for treatment stratification in advanced and recurrent nasopharynx cancer Journal of Clinical Oncology, <b>2018</b> , 36, e18060-e18060	2.2
21	Dependency of radiotherapy and combinatorial radio-immunotherapy responses on the systemic t cell immune response <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12056-12056	2.2
21		2.2
	cell immune response Journal of Clinical Oncology, <b>2018</b> , 36, 12056-12056	
20	cell immune response <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12056-12056  Editorial Comment. <i>Journal of Urology</i> , <b>2019</b> , 201, 291  The role of high-dimensional profiling of the systemic immune response on optimal sequencing of	2.5
20	cell immune response <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12056-12056  Editorial Comment. <i>Journal of Urology</i> , <b>2019</b> , 201, 291  The role of high-dimensional profiling of the systemic immune response on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB) <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 13-13  The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer <i>Journal of</i>	2.5
20 19 18	cell immune response Journal of Clinical Oncology, 2018, 36, 12056-12056  Editorial Comment. Journal of Urology, 2019, 201, 291  The role of high-dimensional profiling of the systemic immune response on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB) Journal of Clinical Oncology, 2019, 37, 13-13  The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer Journal of Clinical Oncology, 2019, 37, 81-81  Clinical and genetic determinants of toxicity and quality-of-life (QOL) outcomes for SBRT in Asian	2.5 2.2 2.2
20 19 18	Editorial Comment. Journal of Urology, 2019, 201, 291  The role of high-dimensional profiling of the systemic immune response on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB) Journal of Clinical Oncology, 2019, 37, 13-13  The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer Journal of Clinical Oncology, 2019, 37, 81-81  Clinical and genetic determinants of toxicity and quality-of-life (QOL) outcomes for SBRT in Asian prostate cancer Journal of Clinical Oncology, 2019, 37, 95-95  A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy Journal of Clinical	2.5 2.2 2.2
20 19 18 17	Editorial Comment. Journal of Urology, 2019, 201, 291  The role of high-dimensional profiling of the systemic immune response on optimal sequencing of radiotherapy (RT) and immune checkpoint blockade (ICB) Journal of Clinical Oncology, 2019, 37, 13-13  The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer Journal of Clinical Oncology, 2019, 37, 81-81  Clinical and genetic determinants of toxicity and quality-of-life (QOL) outcomes for SBRT in Asian prostate cancer Journal of Clinical Oncology, 2019, 37, 95-95  A multicenter prospective observational study of nutritional status on survival in locally advanced nasopharynx cancer treated by induction chemotherapy and chemoradiotherapy Journal of Clinical Oncology, 2019, 37, 6036-6036  Longitudinal circulating EpsteinBarr virus DNA response to induction chemotherapy and chemo-radiotherapy to identify biological phenotypes in EBV-associated nasopharynx of head and	2.5 2.2 2.2 2.2

#### LIST OF PUBLICATIONS

12	Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 117-117	2.2
11	Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP) <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 96-96	2.2
10	Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 49-49	2.2
9	Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5051-5051	2.2
8	Treatment of Viral-Associated HNC (OPC and NPC) <b>2017</b> , 177-188	
7	Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 42-42	2.2
6	Genomic architecture of radioresistant prostate cancer Journal of Clinical Oncology, 2017, 35, 26-26	2.2
5	Dosimetric uncertainties impact on cell survival curve with low energy proton. <i>Physica Medica</i> , <b>2020</b> , 76, 277-284	2.7
4	Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e217	21.7
3	Immunotherapy in Head and Neck Cancer-Ready for Prime Time or More Research Needed?.  International Journal of Radiation Oncology Biology Physics, 2021, 109, 647-650	4
2	Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 249-249	2.2
1	Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2022</b> , 40, 5.e1-5.e13	2.8